Craig A. Dionne, PhD, is one of the founders of Inspyr Therapeutics (formerly known as GenSpera). He has over 25 years of experience in the pharmaceutical industry, including direct experience in identifying promising oncology treatments and bringing them through the clinic. He served for several years as VP Discovery Research at Cephalon, Inc. (now Teva Pharmaceuticals), a biopharmaceutical company, where he was responsible for its oncology and neurobiology drug discovery and development programs. Dr. Dionne also served as Executive Vice President at the Prostate Cancer Research Foundation. In addition to extensive executive experience, Dr. Dionne’s productive scientific career has led to six issued patents and co-authorship of many scientific papers. Dr. Dionne received his PhD from the University of Texas at Austin in 1984.
GenSpera, Inc. (OTCQB: GNSZ) is a development stage oncology company focused on therapeutics that deliver a potent, unique and patented drug directly to tumors. Read More...
Forward Looking Statements
￼This communication may contain forward‐looking statements. Investors are cautioned that statements in this communication regarding potential applications of GenSpera's technologies or the future prospects of the company constitute forward‐looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera’s proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward‐looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.